Michael et al. found that GW4869 (an exosome secretion inhibitor) reduced the formation of amyloid plaques by preventing exosome secretion, and proved that neutral sphingomyelinase 2 (nSMase2) was a potential drug target for AD by interfering with exosome secretion [109]. The gene discussed is SMPD3; the disease is Alzheimer disease.